Merck Extends Timeline On Acceleron Deal, Still Expects Q4 Close

Some Investors Have Voiced Concern About Buyout

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

Merck said it is giving the FTC more time to review the acquisition, but the shift also gives the company leeway to convince any reluctant Acceleron shareholders to trade their shares for cash.

Sand running through an hourglass
Time is not running out yet to close Merck's Acceleron acquisition • Source: Alamy

Merck & Co., Inc. is giving the US Federal Trade Commission more time to review its $11.5bn all-cash acquisition of Acceleron Pharma, Inc. in a move that also extends the deadline for Acceleron investors to tender their shares of the company. Merck, whose bid has been described as too low by some Acceleron shareholders, still expects the deal to close during the fourth quarter of 2021.

Merck said late on 29 October that it has withdrawn its Premerger Notification and Report Form under the Hart-Scott-Rodino Antitrust...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

Test Roche Head Of Pharma Strategy Karsten Jung On Rebuilding The Portfolio

 
• By Jessica Merrill

The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.

Scrip-Business (Free-1): Top-Selling Drugs 2024: Keytruda, Ozempic And Dupixent Dominate

 
• By Nabil

Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.

Partnered By

Nancy Testing Partnered Content

This is a short description.

Pierre Fabre Pushes To Be Partner Of Choice For Budding Biotechs

 
• By Kevin Grogan

Francesco Hofmann, head of R&D at the mid-sized French group, tells Scrip that its strategy of not playing in the spaces that are dominated by big pharma is paying off.

More from Business

How A New Healthcare Dialogue Is Driving Market Access In Mexico

Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.